Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD, Maarten L Janmaat, PhD, Peter Boross, PhD, Jeroen van den Brakel, Wessel ten Hagen, Sanne van Dooremalen, Sieto Bosgra, PhD, Bart ECG De Goeij, PhD, Grietje Andringa, Laurens Kil, PhD, A Kate Sasser, PhD, Tahamtan Ahmadi, MD PhD, David Satijn, PhD, Esther CW Breij, PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140313

Published: 2020

Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135874

Published: 2020

Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson

Blood (2014) 124 (21): 84.

https://doi.org/10.1182/blood.V124.21.84.84

Published: 2014

Journal Articles

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

Elise A. Chong, MD, Tahamtan Ahmadi, MD, PhD, Nicole A. Aqui, MD, Sunita D. Nasta, MD, Jakub Svoboda, MD, Kristy M. Walsh, BS, Amanda Gordon, CRNP, Stephen J. Schuster, MD

Blood (2013) 122 (21): 250.

https://doi.org/10.1182/blood.V122.21.250.250

Published: 2013

Journal Articles

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Marc Hoffmann, MD, Tahamtan Ahmadi, MD, PhD, Erin Cobain, MD, Alison Loren, Noelle V Frey, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 4950.

https://doi.org/10.1182/blood.V118.21.4950.4950

Published: 2011

Journal Articles

B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy

Erin Cobain, MD, Tahamtan Ahmadi, MD, PhD, Marc Hoffmann, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Jakub Svoboda, MD, Selina Luger, MD, Edward A. Stadtmauer, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 2689.

https://doi.org/10.1182/blood.V118.21.2689.2689

Published: 2011

Journal Articles

Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

Tahamtan Ahmadi, MD, PhD, Elise A. Chong, BA, Amanda Gordon, CRNP, Nicole A. Aqui, MD, YinYan Xu, Jakub Svoboda, MD, Sunita D. Nasta, MD, Stephen J. Schuster, MD

Blood (2011) 118 (21): 266.

https://doi.org/10.1182/blood.V118.21.266.266

Published: 2011

Journal Articles

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Jennifer McQuade, MD, Tahamtan Ahmadi, MD, PhD, David Porter, Noelle Frey, Alison Wakoff Loren, MD, MS, Steven C. Goldstein, MD, Jakub Svoboda, MD, Edward Stadtmauer, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2010) 116 (21): 3570.

https://doi.org/10.1182/blood.V116.21.3570.3570

Published: 2010

Journal Articles

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.

Tahamtan Ahmadi, MD, PhD, Elise A. Chong, BA, Amanda Gordon, BA, BSN, RN, Nicole A. Aqui, MD, Lisa H. Downs, CRNP, Leah Leinbach, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Stephen Janofsky, Tapan N. Maniar, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD

Blood (2009) 114 (22): 1700.

https://doi.org/10.1182/blood.V114.22.1700.1700

Published: 2009

Journal Articles

Primary Antigen-Specific B Cells: A Novel Approach to Cellular-Based Immunotherapy.

Tahamtan Ahmadi, MD, PhD, Nathalie Weizmann, MS, Yvonne A. Efebera, MD, David H. Sherr, PhD

Blood (2006) 108 (11): 3717.

https://doi.org/10.1182/blood.V108.11.3717.3717

Published: 2006

NARROW

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy

Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.

Primary Antigen-Specific B Cells: A Novel Approach to Cellular-Based Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only